Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2022 / Sep / Shifting the Focus
Omics Analytical science Molecular Pathology

Shifting the Focus

How noninvasive proteomic biomarkers could improve liver disease diagnosis and management

By Liv Gaskill 09/27/2022 News 1 min read

Share

Alcohol-related liver disease (ALD) frequently leads to cirrhosis and is responsible for over half of liver-related deaths worldwide – but, despite its prevalence, there is still much to understand about the pathological features behind the disease. About 75 percent of patients with ALD remain undiagnosed until after decompensated cirrhosis has occurred, which leaves them with no good pharmaceutical treatment options. Catching ALD at the early, asymptomatic stage is the solution, but sufficiently accurate diagnostics are invasive – creating a clear need for a better understanding of the disease’s key pathophysiological features (fibrosis, inflammation, and steatosis) and, crucially, for accurate, minimally invasive biomarkers.

In search of such biomarkers, researchers used mass spectrometry (MS)-based proteomics to investigate the pathological features of ALD and the diagnostic and prognostic potential of liver and plasma proteome changes (1). Their proteome-profiling workflow demonstrated major proteome changes during ALD progression and helped them identify biomarker panels to simultaneously detect fibrosis stage ≥F2, mild inflammatory activity, and steatosis. Fibrosis was found to have the largest impact on proteome remodeling.

When benchmarked against existing tests, the biomarker panel demonstrated comparable or superior performance for detecting significant fibrosis and mild inflammatory activity. The researchers also extracted data from electronic health records to show high prognostic performance for future liver-related events and all-cause mortality.

The study provides a foundation for potential future use of routine MS-based liver disease testing, but further research must address some limitations, such as cost effectiveness for clinical practice and the need to exclude the possibility of blood contamination during correlation analysis between liver and plasma.

Credit: People illustrations from Shutterstock.com

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. L Niu et al., Nat Med, 28, 1287 (2022). PMID: 35654907.

About the Author(s)

Liv Gaskill

During my undergraduate degree in psychology and Master’s in neuroimaging for clinical and cognitive neuroscience, I realized the tasks my classmates found tedious – writing essays, editing, proofreading – were the ones that gave me the greatest satisfaction. I quickly gathered that rambling on about science in the bar wasn’t exactly riveting for my non-scientist friends, so my thoughts turned to a career in science writing. At Texere, I get to craft science into stories, interact with international experts, and engage with readers who love science just as much as I do.

More Articles by Liv Gaskill

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Turning Tides
Omics
Turning Tides

January 9, 2024

3 min read

A new study shows evidence for sustained human-to-human transmission of mpox since 2016

“Pop” Goes the Sensor
Omics
“Pop” Goes the Sensor

January 19, 2022

1 min read

A new device could help scientists identify signs of arrhythmia, heart attack, and cardiac fibrosis

Improving Risk Stratification
Omics
Improving Risk Stratification

February 3, 2022

1 min read

Two genes have been identified that may be linked to prostate cancer outcomes

The Ultimate Vision for Rare Disease
Omics
The Ultimate Vision for Rare Disease

February 28, 2022

1 min read

Genomics and computational pathology can take rare disease diagnostics to the next level

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.